Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Pyrazole → 3-(1-{[2-(1H-pyrazol-1-yl)-3',5'-bis(trifluoromethyl)biphenyl-4-yl]carbonyl}pyrrolidin-3-yl)pyridine
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | Pyrazole | HCID 1048 | — |
| 반응물 | Salicylaldehyde oxime | HCID 7200 | — |
| 반응물 | Cesium carbonate | HCID 10796 | — |
| 반응물 | 3-(1-{[2-Bromo-3',5'-bis(trifluoromethyl)biphenyl-4-yl]carbonyl}pyrrolidin-3-yl)pyridine | HCID 86657753 | — |
| 촉매 | HCID 178419072 | HCID 178419072 | — |
| 용매 | Acetonitrile | HCID 6342 | — |
| 생성물 | 3-(1-{[2-(1H-pyrazol-1-yl)-3',5'-bis(trifluoromethyl)biphenyl-4-yl]carbonyl}pyrrolidin-3-yl)pyridine | HCID 46847591 | — |
반응 단계
A solution of 3b (54.0 mg, 0.099 mmol), pyrazole (50.7 mg, 0.745 mmol), salicylaldoxime (19.8 mg, 0.145 mmol), copper(I) oxide (16.6 mg, 0.116 mmol) and cesium carbonate (265 mg, 0.812 mmol) in acetonitrile (1.00 mL) was heated to 120° C. in a sealed microwave vial for a total of 60 min. The reaction mixture was cooled to rt, concentrated in vacuo, and the resulting crude residue was purified by preparative reversed phase HPLC on YMC Pack Pro C18 stationary phase (CH3CN/H2O as eluent, 0.05% TFA as modifier), followed by lyophilization of the purified fractions to afford the title compound 10a. m/z (ES) 531 (MH)+.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08367679B2 |
| 출처 데이터셋 | uspto-grants-2013_02 |
| ORD ID | ord-a453bc123ad646129051bb5ef7295e14 |
| 출처 메모 | uspto-grants-2013_02 |